Felipe de Arriba

Hospital General Universitario Morales Meseguer — Spain

Medicine · Health Sciences

40h-index8.1kcitations328works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(277), Protein Degradation and Inhibitors(135), Chemokine receptors and signaling(56), Peptidase Inhibition and Analysis(44), Cancer Treatment and Pharmacology(41)

Publications327 total

Real-world evidence of measurable residual disease assessment in multiple myeloma
Blood Advances·2025Open Access
Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial
Blood·2025Open Access
Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd
Blood·2025Open Access
Immune biomarkers of increased risk of infection in multiple myeloma (MM)
Blood·2025Open Access
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
The Lancet Haematology·2025· 1 cited
Final Analysis of the GEM-BELA-VRd Phase II Trial: Belantamab Mafodotin Plus VRd in Newly Diagnosed Transplant-Eligible Myeloma After 2 Years of Maintenance with Belantamab and Lenalidomide
Clinical Lymphoma Myeloma & Leukemia·2025
Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Follow-Up
Clinical Lymphoma Myeloma & Leukemia·2025
Real-World Use of Melflufen Plus Dexametasone in Relapsed/Refractory Multiple Myeloma: A Retrospective Study from the Valencian Community and the Region of Murcia (Spain)
Clinical Lymphoma Myeloma & Leukemia·2025
Efficacy and Safety of Iberdomide, Daratumumab, and Dexamethasone, in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients: Initial Analysis of the GEM-IBERDARAX trial
Clinical Lymphoma Myeloma & Leukemia·2025
Visceral leishmaniasis in heavily pretreated multiple myeloma patients a case series of 17 patients from the Mediterranean Coast of Spain
Annals of Medicine·2025Open Access
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment
Blood·2025· 9 citedOpen Access
Supplemental Figure 1 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
2025Open Access
Supplemental Figure 3 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
2025Open Access
Supplemental Table 3 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
2025Open Access
Supplemental Figure 2 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
2025Open Access
Supplemental Table 8 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
2025Open Access
Supplemental Table 9 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
2025Open Access
Supplemental Table 1 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
2025Open Access
Supplemental Table 6 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
2025Open Access
Supplemental Table 2 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
2025Open Access
page 1 of 17Next →

Frequent Co-authors

Jesús F. San Miguel(42), Juan José Lahuerta(40), Albert Oriol(37), María‐Victoria Mateos(31), Javier de la Rubia(29), Joan Bladé(26), Joaquín Martínez‐López(26), Luis Palomera(24), Miguel‐Teodoro Hernández(23), Laura Rosiñol(23), Bruno Paiva(22), Joan Bargay(22), Adrían Alegre(20), Norma C. Gutiérrez(17), Anna Sureda(15), José García‐Laraña(13), Ana-Isabel Teruel(12), María‐Belén Vídriales(12), María José Terol(12), Felipe Prósper(11)